A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 4, 2001, Pages 347-354

  Malingre M M ^a   Beijnen, J H ^a   Rosing, H ^a   Koopman, F J ^a   Van Tellingen, O ^a   Duchin, K ^a   Ten Bokkel Huinink, W W ^a   Swart, M ^a   Lieverst, J ^a   Schellens, J H M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cyclosporin A; Oral paclitaxel; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A; GRANISETRON; PACLITAXEL; ANTINEOPLASTIC AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; VOMITING; AREA UNDER THE CURVE; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CYCLOSPORINE; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL;

EID: 0034743369     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000226     Document Type: Article

References (43)

1. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer
2. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833
3. Relative performance of specific and nonspecific fluorescence immunoassay for cyclosporin in transplant patients
4. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation
5. Suspected anaphylactic reaction to Cremophor EL
6. Pharmacology of drugs that alter multidrug resistance in cancer
7. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
8. Noncompartmental analysis based on statistical moment theory
9. Bioavailability of low dose oral etoposide
10. Taxol (paclitaxel): Mechanisms of action
11. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
12. Taxanes: A new class of antitumor agents
13. 2 as a 3-hour infusion
14. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography
15. High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine
16. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and sequencing study in patients with non-small cell lung cancer
17. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
18. Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines
19. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines
20. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines
21. Phase I and pharmacokinetic study of oral paclitaxel
22. Taxol binds to cellular microtubules
23. Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration
24. Co-administrators of cyclosporin enables oral therapy with paclitaxel
25. Co-administration of cyclosporin A enables oral therapy with paclitaxel
26. Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile
27. Clinical pharmacokinetics and pharmacodynamis of paclitaxel: A 3-hour infusion versus a 24-hour infusion
28. Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units
29. Paclitaxel (Taxol)
30. Promotion of microtubule assembly in vitro by taxol
31. Human cytochrome P450 3A4: Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase
32. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography
33. Tissue distribution, metabolism and excretion of paclitaxel in mice
34. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
35. Limited oral bioavailability and active epithelial secretion of paclitaxel caused by P-glycoprotein in the intestine
36. Methotrexate bioavailability after oral and intramuscular administration in children
37. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
38. Cremophor EL causes (pseudo)-non-linear pharmacokinetics of paclitaxel in patients
39. Hypersensitivity reactions from Taxol
40. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration